Hematologic Oncology

Moshe Talpaz, MD, discusses best practices in monitoring patients with CML and applying multidisciplinary care.

Daniel DeAngelo, MD, PhD, provides his perspective on improving CML care through dose adjustment or treatment discontinuation.

Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.

Katja Weisel, MD, shares recommended strategies for the prevention and management of potential ocular effects of belantamab mafodotin in multiple myeloma.

Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.

Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Experts discuss lack of consensus in diagnosis of ITP and challenges physicians face.

ITP experts share considerations in the treatment of pregnant patients with ITP.

Aaron T. Gerds, MD, MS, discusses the use of TKIs, targeted agents, JAK inhibitors, and cellular therapy in hematologic malignancies.

An overview of the general toxicities patients may experience while undergoing therapy for chronic myeloid leukemia.

A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.

Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.

A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.

We had the pleasure of speaking with faculty from an OncLive® Institutional Perspectives in Cancer webinar on hematologic malignancies, hosted in partnership with Cleveland Clinic, to discuss current practice patterns and emerging therapies in chronic myeloid leukemia, chronic lymphocytic leukemia, myelofibrosis, and acute lymphoblastic leukemia.

Andrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

Drs Bussel, Piatek and Kessler discuss treatment of older patients with ITP.

Dr Bussel discusses the use of fostamatinib in patients who have progressed on TPO agents.

Treatment with rituximab prior to COVID-19 vaccination nearly halved the number of patients with B-cell non-Hodgkin lymphoma who developed blocking antibodies following COVID-19 vaccination compared with healthy controls.